




# Pediatric Uncomplicated Acute Otitis Media Empiric Treatment Algorithm

[Bibliography](#)

[Disclaimers](#)

**Uncomplicated acute otitis media:** a middle ear infection that is **limited** to the middle ear cleft. It is characterized by: rapid onset of symptoms, middle ear effusion, signs and symptoms of middle ear inflammation such as fever, otalgia, and ear discharge.



[Dosing recommendations](#)

**Additional Information**

- [Clinical Pearls](#)
- [Pathogens](#)
- [Treatment failure](#)
- [AAP Guidelines for the Diagnosis and Management of AOM<sup>1</sup>](#)
- [AAP Red Book Systems-Based Treatment Table<sup>2</sup>](#)
- [Bibliography](#)

**Treatment Duration<sup>2</sup>**

- < 2 y or severe symptoms: 10 days
- 2 – 5 y: 7 days
- > 5 y: 5 days

**Treatment Considerations**

- Cefdinir is not preferred for treatment of pediatric bacterial infections due to (1) poor pharmacokinetic (PK) characteristics; (2) high rates of resistance; and (3) broad but mismatched spectrum of coverage<sup>3,4,5</sup>
- Acetaminophen or ibuprofen are recommended for treatment of mild to moderate pain
- Amoxicillin-clavulanate products are not interchangeable. Incorrect ratios could lead to subtherapeutic concentrations or severe diarrhea. High-dose, BID regimens should use 14:1 or 16:1 formulations: 600mg/42.9mg per 5 mL (ES) or 1000mg/62.5mg (Extended Release) tablet
- Up to 90% of penicillin allergies are misdiagnosed. Always clarify history of allergy and de-label if appropriate (e.g. family history without patient history). For more information on patient screening, contact the ASP pharmacist (502-629-5568) or consider referral to outpatient allergy.

**Common AOM Bacterial Pathogens**

- *Streptococcus pneumoniae*
- Nontypeable *Haemophilus influenzae*
- *Moraxella catarrhalis*

**Treatment Failure**

- After 48-72h of failure of initial antibiotic treatment (dosing below)
- First-line:
  - Amoxicillin-clavulanate
  - IM Ceftriaxone
- Alternative:
  - Clindamycin +/- 3rd generation cephalosporin (cefdinir, cefpodoxime, ceftriaxone)
  - Consider tympanocentesis or consultation with a specialist

**Dosing Recommendations**

- Amoxicillin 80-90 mg/kg/day oral BID (max 4,000 mg/day)
- Amoxicillin-clavulanate 90 mg/kg per day oral in 2 divided doses (max 4,000 mg amoxicillin/day)
  - Using ES-600 suspension or 1000 mg/62.5 mg ER tablet
- Cefdinir 14 mg/kg/day oral BID (max 600 mg/day)
  - 2 doses daily preferred for PK characteristics
- Cefuroxime 30 mg/kg/day oral BID (max 500 mg/dose)
- Cefpodoxime 10 mg/kg/day oral BID (max 200 mg/dose)
- Ceftriaxone 50 mg/kg IM or IV per day for 1-3 days

**Additional Information**

- [Back to algorithm](#)

**Bibliography**

1. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. *Pediatrics*. 2013 Mar 1;131(3):e964-99.
2. Committee on Infectious Diseases, System-based treatment table editors: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. *Red Book 2021-2024 Report of the Committee on Infectious Diseases*. 32 ed. Itasca, IL: American Academy of Pediatrics; 2021:990-1003.
3. Wattles B, Vidwan N, Ghosal S, Feygin Y, Creel L, Myers J, Woods C, Smith M. Cefdinir use in the Kentucky Medicaid population: a priority for outpatient antimicrobial stewardship. *Journal of the Pediatric Infectious Diseases Society*. 2021 Feb;10(2):157-60.
4. Parker S, Mitchell M, Child J. Cepem antibiotics: wise use today preserves cure for tomorrow. *Pediatr Rev* 2013; 34:510—23; quiz 523—4.
5. Harrison CJ, Woods C, Stout G, et al. Susceptibilities of *Haemophilus influenzae*, *Streptococcus pneumoniae*, including serotype 19A, and *Moraxella catarrhalis* pediatric isolates from 2005 to 2007 to commonly used antibiotics. *J Antimicrob Chemother* 2009; 63:511—9.

This work was supported, in part, by the Kentucky Cabinet for Health and Family Services Department for Medicaid Services under a State University Partnership contract; Norton Children's Hospital; and the University of Louisville School of Medicine, Department of Pediatrics.

**Additional Information**

- [Back to Algorithm](#)
- [Back to Clinical Pearls](#)

The policies set forth in this policy library do not establish a standard to be followed in every case. It is impossible to anticipate all possible solutions that may exist and to prepare policies for each. These policies should be considered guidelines with the understanding that departures from them may be required at times. Accordingly, it is recognized that those individuals employed in providing healthcare are expected to use their own judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. If a policy contains references to clinical literature or other resources, such as Lippincott, Ovid, and/or Elsevier, these resources are only intended to support the reasoning for adoption of certain guidelines contained herein. It is not an endorsement of any article or text as authoritative. Norton Healthcare specifically recognizes there may be articles or texts containing other opinions on point that may be helpful and valid which would support other care or actions, given a particular set of circumstances. No literature is ever intended to replace the education, training and experience or exercise of judgment of the healthcare providers.

Last update: 12/2024

Contact: [adam.isacoff@nortonhealthcare.org](mailto:adam.isacoff@nortonhealthcare.org)

**Additional Information**

- [Back to Algorithm](#)
- [Back to Clinical Pearls](#)